en
/
sv
About Elicera
Elicera in brief
Board
Team
Advisors
Elicera's history
Immuno-oncology
What is immuno-oncology?
CAR T-cell therapy
Oncolytic virus
Technology
CAR T-cell therapy
Challenges
Mode-of-action
Scientific publications
Pipeline
Pipeline
ELC-301
ELC-401
ELC-201
ELC-100
Clinical trials
Patent portfolio
Investors
Press Releases
Corporate Governance
the Share
Financial Reports
Financial Calendar
Events
Share issues
Analyst Coverage
News
News
Press Releases
Events
Contact
en
/
sv
Press Releases
Subscribe
2026
2025
2024
2023
2022
2021
2020
All
Regulatory
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Feb 23, 2024
2024
Press Release Regulatory
The subscription period in Elicera Therapeutics’ rights issue of units starts today
Regulatory
Read more
Feb 21, 2024
2024
Press Release Regulatory
Elicera Therapeutics publishes prospectus in connection with rights issue of units
Regulatory
Read more
Feb 16, 2024
2024
Press Release Non-regulatory
Elicera Therapeutics' abstract on the iTANK platform's potential to enhance CAR T-cell treatment of solid tumors accepted for presentation at ISCT 2024
Read more
Feb 16, 2024
2024
Press Release Non-regulatory
Elicera invites to investor meetings on February 28[th] and 29[th] 2024
Read more
Feb 13, 2024
2024
Press Release Regulatory
Elicera Therapeutics AB (publ) Year-End Report 1 January – 31 December 2023
Regulatory
Read more
Feb 9, 2024
2024
Press Release Non-regulatory
Elicera Therapeutics receives approval to initiate clinical Phase I/II-study CARMA with CAR T-cell therapy ELC-301 in B-Cell lymphoma
Read more
Jan 18, 2024
2024
Press Release Regulatory
NOTICE OF EXTRAORDINARY GENERAL MEETING IN elicera therapeutics AB
Regulatory
Read more
Jan 18, 2024
2024
Press Release Regulatory
Elicera’s Board of Directors proposes a rights issue of units of approximately SEK 64 million
Regulatory
Read more
Jan 17, 2024
2024
Press Release Non-regulatory
Elicera Therapeutics’ co-founder Magnus Essand invited to present the company's CAR T-cell projects at the world's largest cancer immunotherapy conference, CICON
Read more
Jan 9, 2024
2024
Press Release Non-regulatory
Elicera Therapeutics participates in a collaborative project for the development of improved CAR T-cell production that has been awarded research support of SEK 850 thousand
Read more
Dec 22, 2023
2023
Press Release Non-regulatory
Elicera Therapeutics' co-founder receives a grant totalling 4.8 MSEK from the Swedish Childhood Cancer Fund to support CAR T-cell research
Read more
Dec 22, 2023
2023
Press Release Non-regulatory
Elicera Therapeutics submits GMP validation data to the Swedish Medical Products Agency for the CARMA study to supplement the conditionally approved clinical trial application
Read more
Nov 30, 2023
2023
Press Release Regulatory
Elicera Therapeutics changes Certified Adviser and Liquidity provider to Carnegie Investment Bank AB (publ)
Regulatory
Read more
Nov 14, 2023
2023
Press Release Regulatory
Elicera Therapeutics AB (publ) Interim Report January 1 – September 30, 2023
Regulatory
Read more
Oct 31, 2023
2023
Press Release Regulatory
Nomination Committee for Elicera therapeutics appointed
Regulatory
Read more
Sep 8, 2023
2023
Press Release Non-regulatory
Elicera Therapeutics receives Notice of Allowance for Chinease patent protecting the iTANK platform
Read more
Aug 29, 2023
2023
Press Release Regulatory
Elicera Therapeutics AB (publ) Interim Report 1 January – 30 June 2023
Regulatory
Read more
Aug 10, 2023
2023
Press Release Non-regulatory
Elicera Therapeutics publishes a scientific article in Nature Communications about the CAR T construct in the ELC-401 program
Read more
Jul 11, 2023
2023
Press Release Non-regulatory
Elicera Therapeutics receives Notice of Allowance for European patent protecting the iTANK[TM] platform
Read more
May 16, 2023
2023
Press Release Regulatory
Elicera Therapeutics AB (publ) Interim Report 1 January – 31 March 2023
Regulatory
Read more
Previous
+ Load more
4 / 7
Sign up for Press Releases
I consent to Elicera Therapeutics storing and using my information to send press releases and financial information by email. Read our
privacy policy
.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
By continuing to browse this website you agree to cookies being stored on your device in order to improve the experience and analyze how it is being used. Read more in our
Integrity policy
.
Deny
Accept